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Targeted Knockdown of 
Overexpressed VEGFA or VEGF164 
in Müller cells maintains retinal 
function by triggering different 
signaling mechanisms
Silke Becker1, Haibo Wang1, Aaron B. Simmons1, Thipparat Suwanmanee3, Gregory J. Stoddard2, 
Tal Kafri3 & M. Elizabeth Hartnett1
Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) 
that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety 
concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-
VEGFA with short-hairpin RNAs to VEGFA or VEGF164 via subretinal lentivirus delivery (L-VEGFAshRNA, 
L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat 
mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina 
(IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared 
to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence 
tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer 
thicknesses in L-VEGFAshRNA or L-VEGF164shRNA  compared to control. Ganzfeld electroretinograms 
were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin 
(EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, 
neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. 
In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with 
EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, 
and particularly VEGF164, in Müller cells may have fewer deleterious effects than nonselective VEGFA 
inhibition to all cells in the retina.
Retinopathy of prematurity (ROP) is a leading cause of childhood vision loss and blindness worldwide1 and is 
increasing with survival of extremely preterm infants2. A major reason for vision loss is untreated severe ROP that 
leads to total retinal detachment. With premature birth, there is incomplete vascularization of the human infant 
retina with subsequent delayed physiologic retinal vascular development. When the infant is moved from supple-
mental oxygen to room air, poor oxygenation of the avascular retina stimulates disordered growth of retinal blood 
vessels into the vitreous rather than into the avascular retina. This intravitreal neovascularization can develop into 
severe, vision-threatening ROP3. Treatment of severe ROP is evolving with the use of anti-angiogenic agents that 
inhibit the bioactivity of vascular endothelial growth factor (VEGF) instead of standard care laser photocoagu-
lation of the peripheral avascular retina4. VEGF is an important angiogenic factor involved in the pathogenesis 
of severe ROP5, but it is also important in the development of the retina6. Intravitreal neutralizing antibodies to 
VEGF also reduce VEGF in the bloodstream7 raising concerns of adverse effects on other developing organs in 
the preterm infant8. Besides these concerns on developing retina and organs, intravitreal anti-VEGF agents have 
altered the natural course of ROP with reports of reactivation of severe ROP and retinal detachment over a year 
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after intravitreal injection9. Although clinical trials are testing lower doses of neutralizing VEGF antibodies in 
severe ROP10, a safe and effective dose remains elusive.
Studies in animal models representative of severe ROP in humans show that inhibition of VEGF with neu-
tralizing intravitreal antibodies at certain doses effective at inhibiting retinopathy also reduce pup growth, reduce 
retinal capillary density and result in recurrent intravitreal neovascularization in association with activation of 
angiogenic signaling pathways in the retina11,12. We previously tested the hypothesis that targeted VEGF inhibi-
tion in Müller cells that overexpress VEGF would reduce aberrant angiogenesis into the vitreous. We developed 
short hairpin RNAs (shRNAs) to VEGFA under the control of a cell-specific promoter to inhibit overexpression of 
VEGFA in Müller cells13 and found reduced intravitreal neovascularization without adverse effects on physiologic 
retinal vascular development. However, knockdown of VEGFA led to cell death and thinning of the outer and 
inner nuclear layers in transduced retinas14.
An alternative splice variant of VEGFA, VEGF164, is overexpressed by repeated oxygen fluctuations, a stress 
associated with increased risk of ROP15,16. Mice lacking VEGF164 but engineered to express the other two rodent 
isoforms, VEGF120 and VEGF188, appeared to have normal retinal development16. These observations raise the 
possibility that inhibition of VEGF164 in Müller cells would be safer than inhibition of all VEGFA isoforms. 
Indeed, selective knockdown of VEGF164 in Müller cells with a lentivirus carrying VEGF164 shRNA driven by 
a cell specific promoter resulted in reduced intravitreal neovascularization in a rat oxygen-induced retinopathy 
(OIR) model14 without thinning of the outer nuclear layer in the short-term. In this study, we determined whether 
long-term inhibition of overexpressed VEGF164 specifically in Müller cells would be sufficient to inhibit intravit-
real neovascularization without causing functional or structural loss to the retina and to explore effects of targeted 
VEGF knockdown in Müller cells on the retina.
Results
Course of Lentiviral Knockdown of VEGFA or VEGF164 on Intravitreal Neovascularization and 
Peripheral Avascular Retina in the Rat OIR Model. We first determined if knockdown of VEGFA or 
VEGF164 within Müller cells would adversely increase avascular/total retinal area (AVA) or lead to a recurrent 
intravitreal neovascular/total retinal area (IVNV) long-term in the OIR model since recurrence was seen follow-
ing successful inhibition of IVNV with intravitreal neutralizing antibodies against rat VEGF16411. To determine 
this, lentiviruses were used to deliver vectors containing the cell specific CD44 promoter to drive the expression 
of shRNAs targeting VEGFA (L-VEGFAshRNA), VEGF164 (L-VEGF164shRNA) or luciferase (L-lucifshRNA) as 
a non-mammalian control within Müller cells. All the lentiviral constructs contained a GFP reporter to confirm 
successful transduction14. Efficiency was previously confirmed in HEK 293 GFP reporter cell lines expressing 
either rat VEGF120 to assess VEGFA knockdown or VEGF164 to assess the VEGF164 splice variant. Each reporter 
cell line was transfected with a plasmid DNA expressing VEGFA shRNA or VEGF164 shRNA and found to 
have reduced VEGF120 mRNA from VEGFA shRNA or VEGF164 mRNA by both plasmids compared to control 
luciferase shRNA plasmid13. Specificity of the lentiviruses had been confirmed in vitro by visualization of GFP in 
transduced rat Müller cells (rMC-1 cells, kindly provided by V. Sarthy) with no GFP visualized in human retinal 
microvascular endothelial cells (hRMVECs) and in vivo by GFP visualization consistent with transduced Müller 
cell endfeet with the Micron IV (Fig. 1) and confirmed on glutamine synthetase and GFP-colabeled cryosec-
tions13,14. Only eyes with confirmed Müller cell transduction were included in subsequent analyses. At p18, a time 
point of IVNV in the rat OIR model, significant inhibition of IVNV was detected (**P = 0.002 L-VEGFAshRNA 
and *P = 0.014 L-VEGF164shRNA vs. L-lucifshRNA) with no adverse effects to AVA (Fig. 2), as previously 
found14. At p32, a time point when the rat OIR model naturally undergoes regression of IVNV and ongoing vas-
cularization of the peripheral avascular retina, there was no difference in AVA or IVNV between L-lucifshRNA 
control and either L-VEGFAshRNA or L-VEGF164shRNA (Fig. 2), providing evidence that Müller cell specific 
knockdown of VEGFA or VEGF164 did not lead to recurrent retinopathy.
Müller cell knockdown of VEGFA or VEGF164 thins outer nuclear and photoreceptor lay-
ers. Previously, TUNEL positive cells were increased in rat OIR transduced retinas at p18 with later thin-
ning of retinal layers measured on immunohistochemical (IHC) sections at p25 in L-VEGFAshRNA but 
not L-VEGF164shRNA treated eyes14. Therefore, we predicted retinal structure would be altered at p32 in 
L-VEGFAshRNA-, but not in L-VEGF164shRNA- treated eyes. However, we detected thinning of photore-
ceptor and outer nuclear layers (PRS + ONL) by IHC in both L-VEGFAshRNA and L-VEGF164shRNA treated 
eyes compared to L-lucifshRNA controls measured at p32 (Fig. 3a–d, p = 0.001 L-VEGFAshRNA; p = 0.049 
L-VEGF164shRNA vs. L-lucifshRNA). In contrast, the inner nuclear (INL) was thicker in L-VEGF164shRNA 
compared to either L-VEGFAshRNA or L-lucifshRNA (Fig. 3e, p = 0.001 L-VEGFAshRNA; p = 0.004 
L-lucifshRNA vs. L-VEGF164shRNA), as were the inner plexiform and ganglion cell layers (IPL + GCL) (Fig. 3f, 
p = 0.011 L-VEGFAshRNA; p = 0.003 L-lucifshRNA vs. L-VEGF164shRNA) and total retina (Fig. 3g, p = 0.002 
L-VEGFAshRNA; p = 0.016 L-lucifshRNA vs. L-VEGF164shRNA). There was little evidence of cell death deter-
mined by TUNEL + staining in any group including subretinal PBS control (data not shown), suggesting that 
the lentivirus itself was not toxic at this time point. Additionally, retinal structure was analyzed in vivo with 
spectral-domain optical coherence tomography (OCT). For this analysis, only GFP-positive retinas trans-
duced with L-VEGFAshRNA, L-VEGF164shRNA or L-lucifshRNA were imaged and layer thicknesses meas-
ured (Fig. 4a–f). There was significant thinning of the photoreceptor and outer nuclear layers (PRS + ONL) in 
L-VEGFAshRNA and L-VEGF164shRNA treated eyes compared to L-lucifshRNA control (Fig. 4g, P < 0.001 
L-VEGFAshRNA and P = 0.003 L-VEGF164shRNA vs L-lucifshRNA), but the thicknesses of the INL 
(Fig. 4h), IPL + GCL (Fig. 4i) and total retina (Fig. 4j) were not significantly different in L-VEGFAshRNA or 
L-VEGF164sRNA compared to L-lucifshRNA. Altogether, the findings suggest that knockdown of VEGFA or 
VEGF164 in Müller cells leads to thinning of the photoreceptor and outer nuclear layers, and that knockdown of 
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VEGF164 in Müller cells may increase the thicknesses of the GCL, IPL and INL based on IHC. IHC recorded reti-
nal thickness in both nontransduced and transduced retinal regions, whereas OCT measurements only included 
transduced retina, which may account for differences in the thickness measurements of the INL and IPL + GCL 
by each method. To assess if the lentivirus itself caused thinning, we compared OCTs of L-lucifshRNA to sub-
retinal PBS treated eyes and found no difference in any layer thicknesses (data not shown), suggesting  that the 
lentivirus alone was not principally causing the structural differences observed.
Müller cell knockdown of VEGF or VEGF164 improves retinal function. Inhibition of VEGF has 
been associated with death of retinal cells, such as photoreceptors14, Müller cells17 and retinal ganglion cells18. 
Therefore, thinning of the photoreceptor cell layers by L-VEGFAshRNA or L-VEGF164shRNA treatments 
would be predicted to be associated with reduced retinal function measured as reduced a-wave amplitudes 
by electroretinography. Focal electroretinograms (ERGs) were performed in transduced, GFP-positive retina. 
Compared to L-lucifshRNA treated eyes, there was no significant difference in focal ERG a- or b-wave ampli-
tudes in L-VEGFAshRNA (P = 0.731 and P = 0.08, respectively) or L-VEGF164shRNA (P = 0.322 and P = 0.309, 
respectively) (Fig. 5a–c). This suggested that Müller cell transduction of L-VEGFAshRNA or L-VEGF164shRNA 
did not adversely affect retinal function. In contrast to the focal ERG, which was used to measure function in 
the transduced retina only, the full-field ERG measures function over the entire retina that includes transduced 
and non-transduced regions. Compared to L-lucifshRNA, the full-field ERG a-wave and b-wave amplitudes 
were larger in the L-VEGFAshRNA or L-VEGF164shRNA compared to L-lucifshRNA treated eyes; the a-wave 
for photoreceptor function was significantly larger in eyes transduced with L-VEGF164shRNA(p = 0.049) 
(Fig. 6a,b); and the b-wave for inner retinal and bipolar cell function was significantly larger in eyes transduced 
with L-VEGFAshRNA (P = 0.044) (Fig. 6a and c). These findings suggested that specific knockdown of Müller cell 
VEGFA or VEGF164 led to improved overall retinal function at p32 compared to control L-lucifshRNA.
Müller cell specific VEGF knockdown increases neurotrophic factors and activates survival 
signaling. Inhibition of VEGF with intravitreal neutralizing antibodies can increase Müller cell expression 
of erythropoietin (EPO) through a mechanism involving STAT3 activation and nuclear translocation19. EPO 
Figure 1. Representative fundus images and GFP expression at postnatal days (p)18 and p26 (a,e): after 
subretinal injection of PBS or after subretinal injection with pFmCD44 GFP lentiviruses with shRNA targeted 
against (b,f) luciferase (L-lucifshRNA), (c,g) VEGF-A (L-VEGFAshRNA), (d,h) VEGF164 (L-VEGF164shRNA).
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Figure 2. (a–c) Representative retinal flat mount images of lentivirus-treated retinas at p32 (Scale bar is 
2 mm), (d–e). delineation of area with AVA and IVNV pointed by white arrows (f). IVNV, but not (g). AVA was 
significantly reduced at p18 after knocking down VEGF with either L-VEGFAshRNA or L-VEGF164shRNA 
(*p < 0.05, **p < 0.01 vs. L-lucishRNA; n = 5–8) (†p < 0.001 p32 vs. p18 for each treatment). There was 
no difference in AVA or IVNV between any of the groups at p32 (n = 12 for L-lucifshRNA, n = 9 for 
L-VEGFAshRNA and n = 10 for LVEGF164shRNA).
Figure 3. (a–c) Representative micrographs of cryosections stained with DAPI nuclear stain. (d) Thickness of 
the photoreceptor and outer nuclear layer (PRS + ONL) was significantly reduced in retinas transduced with 
L-VEGFAshRNA or L-VEGF164shRNA. e–g) Thicknesses of the inner nuclear layer (INL), inner plexiform 
layer and ganglion cell layer (IPL + GCL) and total retina were significantly increased in retinas transduced 
with L-VEGF164shRNA (*p < 0.05 vs. L-lucishRNA and vs. L-VEGFAshRNA; n ≥ 16 images). Scale bar in 
d = 25 µm.
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has angiogenic and neuroprotective functions20. Since VEGF is neuroprotective and secreted, it is possible that 
reduced VEGF expressed by Müller cells may trigger other mechanisms in Müller and other retinal cells through-
out the retina to express neuroprotective factors in order to restore retinal function. To address the hypothesis 
that specific Müller cell knockdown of VEGFA or VEGF164 leads to increased expression of protective factors, 
we measured mRNAs at p18 and p32 in retinas for several neurotrophic and neuroprotective factors produced 
by Müller cells. In comparison to L-lucifshRNA-treated eyes, EPO (*P = 0.0248), nerve growth factor (NGF, 
**P = 0.0098), brain-derived neurotrophic factor (BDNF, *P = 0.0234), neurotrophin-3 (NT-3, *P = 0.0271) and 
glial cell-derived neurotrophic factor (GDNF, **P = 0.0053) were increased in L-VEGFAshRNA-treated but not 
in L-VEGF164shRNA-treated retinas at p32 (Fig. 7). EPO, BDNF, NT-3 and GDNF expression was reduced in 
L-lucifshRNA treated eyes at p32 compared to p18. We then addressed the question if Müller cells, knocked 
down for VEGF, expressed neurotrophic factors in an autocrine manner. Isolated and cultured primary rat Müller 
cells (passages 3–5) were transfected with VEGF siRNA or control siRNA and found to have 40% knockdown 
(Fig. 8a, p = 0.013). Real-time PCR performed 48 hours after transduction demonstrated EPO (Fig. 8b, p = 0.008) 
and NT-3 (Fig. 8c, p = 0.0002) significantly increased. The other neurotrophic factors found increased in retinal 
lysates from the rat OIR model were not significantly affected in cultured rat Müller cells stimulated with EPO.
We then asked if EPO would activate signaling pathways in Müller cells that were important for retinal cell 
survival. Rat Müller cells were stimulated with EPO, and activation of extracellular signal regulated kinase 
(ERK) or protein kinase B (PKB/AKT) was determined as phosphorylated ERK (p-ERK) or p-AKT on western 
blots. Both p-ERK and p-AKT (Fig. 8d) were induced 15 minutes after EPO treatment and maintained through 
120 minutes.
Discussion
Excessive VEGF signaling disorders developmental angiogenesis in the preterm infant retina and contributes to 
severe, vision-threatening ROP3. However, VEGF is also important in retinal6,17,21 and other organ development8. 
The infants at greatest risk of severe ROP in the US are often extremely premature infants, born younger than 
28 weeks gestational age and less than 1000 g birth weight. The Extremely Premature Infants in Sweden Study 
(EXPRESS) reported that infants under 28 weeks gestational age who never developed ROP still had reduced ERG 
function and vision at age 6.5 years22,23. These infants also may be the most vulnerable to the effects of VEGF inhi-
bition, because as young, very premature infants, less neural development has occurred than in older premature 
Figure 4. (a–c) MicronIV images showing GFP-transduced areas sampled by OCT. (d–f) Representative 
OCT images. (g) Thickness of the PRS + ONL measured by OCT was significantly reduced in GFP-positive 
areas of retinas transduced with L-VEGFAshRNA (***p < 0.001, n = 4) or L-VEGF164shRNA (**p < 0.01, 
n = 6) compared to L-lucifshRNA (**p < 0.01, ***p < 0.001 vs. L-lucishRNA; n = 9). (h–j). No difference was 
observed in INL, IPL + GCL, or total retina thickness between any of the groups. Scale bar in f = 100 µm.
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infants who have already met some milestones. There are slight differences in ocular volumes between very pre-
mature and older premature infants, making a similar intravitreal dose of anti-VEGF agent more concentrated 
in the younger, smaller eye. Furthermore, it is not safe to measure the amount of VEGF in the infant vitreous in 
order to adjust the dose of anti-VEGF agent. Effects of a single anti-VEGF intravitreal injection in infants include 
persistent avascular retina and later recurrent severe ROP24. Therefore, greater understanding of the relationships 
among glia, the neural retina and vasculature become increasingly important as ever younger and smaller prema-
ture infants are surviving and developing severe ROP.
Anti-VEGF agents enter the circulation and are diluted in the blood volume, which is about 6% of the total 
body weight. Therefore, in different sized infants, the concentration of circulating anti-VEGF agent after a single 
intravitreal dose may vary. Levels of VEGF in the circulation can be reduced for 2 months following a single dose 
of anti-VEGF7. Efforts are needed to modify anti-VEGF dose or agent10, or to target anti-VEGF strategies to cells 
that overexpress it, or to target signaling pathways involved from overexpessed VEGF. We wished to learn more 
about the mechanisms and safety of knocking down overexpressed VEGFA or the splice variant, VEGF164, in 
Müller cells at later time points. The importance and role of Müller cell-derived VEGF in IVNV has been demon-
strated in mouse and rat OIR models13,25. In this study, our goals were to assess longer-term effects of targeted 
VEGF knockdown on retinal structure and function in an experimental model that is representative of many of 
the features of human ROP. As previously reported, IVNV was inhibited at p18 by either experimental lentivirus 
compared to control without an increase in AVA14 and no increase in IVNV or AVA at p32. IVNV and AVA per-
sisted in all groups at p32, but the magnitudes were not different from other studies in which subretinal or ocular 
injections were used26. However, we found thinning of the photoreceptor and ONL layers in L-VEGFAshRNA 
or L-VEGF164shRNA compared to L-lucifshRNA control suggesting that Müller cell knockdown of VEGFA 
or VEGF164 may have harmful effects on photoreceptors. In other models, VEGF has been found to be impor-
tant for photoreceptor health and survival17. Thickening of the INL and IPL + GCL observed by IHC following 
L-VEGF164shRNA may be due to incomplete knockdown of all VEGF isoforms in the retina by this treatment. 
In particular, soluble VEGF120, which is not targeted by L-VEGF164shRNA, may diffuse to and affect the entire 
retina, not only to local areas in the case of cell-associated, longer splice variants. We did not observe a compensa-
tory upregulation of VEGF120 and VEGF164 mRNA by either L-VEGFAshRNA or L-VEGF164shRNA treatments.
In contrast to predicted, function was not worse in transduced areas of L-VEGFAshRNA and 
L-VEGF164shRNA treated eyes measured by focal ERG. Furthermore, full-field ERG amplitudes were increased 
in L-VEGFAshRNA and L-VEGF164shRNA treated eyes compared to L-lucifshRNA. This raised the possibility 
that expression of neuroprotective factors triggered by specific knockdown of VEGFA or VEGF164 in Müller cells 
improved function of the neural retina. Higher a- and b-wave amplitudes observed in the Ganzfeld ERG indicate 
Figure 5. (a) Example traces of scotopic focal ERGs in L-lucifshRNA, L-VEGFAshRNA or L-VEGF164shRNA 
treated animals at p32 (b,c). The amplitudes of the a-wave and b-wave of the scotopic focal ERGs were not 
significantly changed by L-VEGFAshRNA (n = 10) or L-VEGEF164shRNA VEGF164 (n = 13) compared to 
L-lucifshRNA (n = 7).
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that factors, which likely mediate this improvement, are able to diffuse within the retina to non-transduced areas. 
Although L-VEGF164shRNA did not result in detectable upregulation of any of the neuroprotective factors or 
EPO investigated in this study, increased ERG function may be through different pathways or protective factors, 
including expression of VEGF splice variants that were not affected by VEGF164 knockdown.
Better retinal function was observed following treatment with L-VEGFAshRNA or L-VEGF164shRNA com-
pared to L-lucifshRNA control in the full field scotopic ERG despite thinning of the photoreceptor layer. It is not 
yet clear the reason for this observation, but  may depend, in part, on the  degree of knockdown and timing of 
ERG analysis. A previous study in the mouse OIR model27 reported that retinal function did not always correlate 
well to ONL thickness. In the rat OIR model, despite similar thicknesses of the photoreceptor and inner nuclear 
layers, subretinal PBS injection resulted in increased b-wave amplitude compared to pilot hole without injec-
tion26. These findings suggest that the change in ONL thickness does not directly reflect visual function or that 
the timing of the ERG has not aligned with the structure of the retina.
Neurotrophic factors are known to rescue photoreceptors from degeneration28. A previous report showed 
that an intravitreal neutralizing antibody to VEGF increased Müller cell EPO expression in the rat OIR model19. 
EPO also has proposed neuroprotective effects20. Following L-VEGFAshRNA transduction, EPO, GDNF, NT-3, 
NGF and BDNF were all significantly upregulated at p32 but not at p18. These findings supported the notion that 
long-term knockdown of VEGFA activated neurotrophic factors in the retina, whereas knockdown of VEGF164 
(and potentially VEGF188 splice variant) did not. Both L-VEGFAshRNA and L-VEGF164shRNA thinned the pho-
toreceptor and ONL layers, but only L-VEGFAshRNA led to increased expression of neurotrophic factors. On the 
other hand, L-VEGF164shRNA thickened the INL, IPL and GCL without increased expression of neurotrophic 
factors. These findings may represent differences in the degree of VEGF knockdown or timing of events related 
to induced protective pathways on neural processing in the retina, as the INL and IPL involves many connections 
among retinal neurons and glia. For example, if early upregulation of neurotrophic factors occurred following 
L-VEGFAshRNA or L-VEGF164shRNA Müller cell transduction, some protective effects such as increased ERG 
amplitudes with thickening of retinal layers may have occurred at the later p32 time point. There also may be dif-
ferential effects from knockdown of VEGF splice variants. Presence of the two splice variants VEGF120 or VEGF188 
is sufficient for normal retinal vascular development16, but VEGF164 was associated with inflammatory findings 
in experimental retinal models16 and was upregulated by repeated fluctuations in oxygenation15, a risk of severe 
ROP. Therefore, inhibition of VEGF164 may reduce pathology without being as harmful to the retina as inhibition 
of VEGFA. VEGF120 is transcribed from the VEGFA gene by variant splicing, translated and is secreted, whereas 
VEGF164 has a heparin-binding domain rendering it cell-associated also. Great concentrations of secreted VEGF 
may have provided some protective effects manifested as thickened layers of the retina with less stimulus for 
neurotrophic factor expression in the L-VEGF164shRNA treated eyes. An aptamer to inhibit the human analog, 
VEGF165, did not appear to have as beneficial an effect in studies of neovascular AMD29, but other methods of 
Figure 6. (a) Example traces of scotopic Ganzfeld ERGs in L-lucifshRNA, L-VEGFAshRNA or 
L-VEGF164shRNA treated animals at p32. (b) The amplitude of the scotopic a-wave in the Ganzfeld 
ERG was increased in retinas transduced with L-VEGF164shRNA compared to L-lucifshRNA (p = 0.049 
L-VEGF164shRNA vs. L-lucishRNA; n = 12 and n = 10, respectively). (c) The amplitude of the b-wave in the 
scotopic Ganzfeld ERG was significantly increased in retinas transduced with L-VEGFAshRNA compared to 
L-lucifshRNA (p = 0.044 L-VEGFAshRNA vs. L-lucishRNA; n = 11 and n = 10, respectively).
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inhibition may be more effective in OIR or ROP. More study is needed. IHC was performed in the central ret-
ina in all samples. However, some central retinal sections included in thickness measurements likely involved 
non-transduced retina. In contrast, OCTs were performed in transduced retina only as this was visualized as 
GFP-positive. Some of the discrepancy between IHC and OCT measurements may be due to such differences in 
measurements by IHC vs. OCT.
Knockdown of VEGF upregulated NT-3 and EPO in cultured Müller cells. Other cells besides Müller cells 
may have been stimulated to produce other neurotrophic factors when Müller cell-expressed VEGF was inhib-
ited in vivo. Also, NT-3 can bind tyrosine kinase receptors (TrKC and TrKB) and trigger signaling pathways that 
indirectly affect neuroprotective factor expression in other cells at later time points. NT-3 may have been upreg-
ulated in Müller cells following VEGF knockdown as both factors were found to be neuroprotective for photore-
ceptors28. In addition, EPO also has been reported to trigger neuroprotective pathways30 and to increase BDNF 
Figure 7. A significant increase in the mRNA expression of the neurotrophic factors: (a) EPO, (b) NGF, (c) 
BDNF, (d) NT-3 and (e). GDNF was observed in retinas after injection of L-VEGFAshRNA compared to 
L-lucifshRNA at p32 (*p < 0.05, **p < 0.01 and ***p < 0.001 vs. L-lucishRNA at p18; n = 4–5). EPO, BDNF, 
NT-3 and GDNF were decreased in L-lucifshRNA at p32 compared to p18.
Figure 8. Knockdown of VEGFA in rat Müller cells in-vitro increases expression of neurotrophic factors and 
activates survival signaling. a-c: Real time PCR of (a) VEGFA, (b) EPO and (c) NT-3 mRNA in rat Müller cells 
transfected with siRNA targeting rat VEGFA or negative control siRNA (*p < 0.05, **p < 0.01 and ***p < 0.001 
vs. Control siRNA; n = 3); Western blots of: (d) phosphorylated AKT (p-AKT) and (p-ERK) in rat Müller cells 
treated with recombinant EPO (1 unit/ml) for 15, 30 and 120 mins (n = 3) (p-AKT and p-ERK were probed on 
different gels. For each gel, either p-AKT or p-ERK was probed and then reprobed for β-actin so that β-actin 
was probed for each gel. p-AKT and its β-actin were cropped from the same gel. P-ERK and β-actin were 
cropped from the same gel. The full length of the gels were included in Supplemental Fig. 3).
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in Müller cells31. In cultured Müller cells stimulated with EPO, no increased neurotrophic factor expression was 
detected, but EPO activated p-AKT and p-ERK, kinases that are involved in neuroprotective signaling30. Finally, 
there may be differences between lentiviral transduction of VEGFA shRNAs and transfected cultured Müller cells 
with VEGF siRNA.
In conclusion, our study suggests that inhibition of VEGFA splice variants in Müller cells can cause structural 
abnormalities in the retina but also functional improvement of the ERG via expression of neuroprotective factors 
from Müller and other retinal cells known to protect photoreceptors. By selectively targeting VEGF164 in Müller 
cells, protective mechanisms may be through a different mechanism including by expression of secreted shorter 
forms of VEGFA. Selective knockdown of VEGFA or VEGF164 in Müller cell may reduce potential adverse effects 
from nonselective VEGFA inhibition to all cells in the retina, as what occurs with neutralizing intravitreal anti-
bodies to VEGF. Additional studies to test the roles of VEGFA, VEGF164 and EPO on vascular, neural and glial 
mechanisms in the retina and the effects on functioning and development are warranted. These studies provide 
insight into the effects of inhibiting VEGF in retinopathy on retinal structure and function.
Materials and Methods
Lentivector-Driven shRNA. As previously reported14, short hairpin RNAs targeting firefly luciferase 
(accession number M15077, non-mammalian control, luciferase shRNA), rat VEGF164 (accession number 
AF260425, VEGF164 shRNA) and rat VEGFA (accession number NM_031836, VEGF-A shRNA) were embedded 
into a microRNA (miR-30) context. The miR-30/shRNAs were cloned into a lentiviral transfer vector under tran-
scriptional control of a CD44 promoter (pFmCD44.1 GW), with green fluorescent protein (GFP) as a reporter 
gene. Lentiviral vectors were generated and concentrated by transient three-plasmid transfection into 293 T cells 
and ultracentrifugation, respectively, as described earlier32.
Cell culture and transfection. Primary rat Müller cells were isolated from one litter of 8 day old Sprague 
Dawley rat pups using a protocol adapted from Hicks and Courtois33. Briefly, eyes were enucleated and incu-
bated in serum-free Dulbecco’s Modified Eagle’s medium (DMEM)/GlutaMAX at room temperature overnight 
followed by digestion at 37 °C in 0.001 g/mL Trypsin and 70 U/mL collagenase in serum-free DMEM for 20 min 
and wash in DMEM + 10% fetal bovine serum (FBS). Retinas were then dissected in serum-free DMEM and 
dispersed by pipetting until the retinal cell suspension was homogenous. Cells were re-suspended in 10% FBS in 
DMEM, seeded into a 10 cm tissue culture dish and incubated in 5% CO2 at 37 °C. After 6 to 7 days, cultured cells 
were washed with PBS and the cells that did not have Müller cell morphology were removed by rubbing with an 
18 G cannula. Presence of Müller cell markers vimentin and glutamine synthetase by immunostaining were used 
to confirm cell identity (Supplemental Fig. 1). Cells were maintained in 10% FBS, DMEM/GlutaMAX and used 
from passages 3 to 5.
To knockdown VEGFA, rat primary Müller cells, were transfected with silencer selective siRNA targeting 
rat VEGFA, or a silencer selective negative control siRNA using lipofectamine 2000 (Invitrogen, Carlsbad, CA). 
Within 48 hours of transfection, cells were collected for RNA analysis.
RNA isolation, reverse transcription and quantitative real-time PCR of neurotrophic fac-
tors. RNA from retinas or rat primary Müller cells were isolated using a TRI reagent (Sigma Aldrich, St. 
Louis, MO) and RNA concentrations were determined with a Nanodrop 2000 Spectrophotometer (Nanodrop, 
Wilmington, Delaware). RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA). Expression of mRNA coding for rat VEGFA, EPO, NT-3, BDNF, GDNF, 
NGF and the housekeeping gene GAPDH was measured using specific PCR primers (HSC Core, University 
of Utah, Salt Lake City, Utah) and SYBR Green Mastermix (Applied Biosystems) in a Bio-Rad CFX Connect 
Real-Time System (Bio-Rad, Hercules, California). Expression levels for all genes were normalized to the mean 
value of the internal control, GAPDH. Each sample was run in duplicates and changes in gene expression were 
displayed as fold difference of ΔΔ2−CT normalized to samples treated with luciferase shRNA or control siRNA. 
Sequences of the primers used in quantitative real time PCR were listed below:
Rat VEGFA GCTCCTTCACTCCCTCAAATTA (Forward)
    GGTCTCTCTCTCTCTCTCTCTTC (Reverse)
Rat EPO:     AGCAGGAGAGACTGAGAGAA (Forward)
     CCTTGACTACATAGCGAGTTCC (Reverse)
Rat NT-3:   CATAAGAGTCACCGAGGAGAGTA (Forward)
   GATCTCTCCCAACACTGTAACC (Reverse)
Rat BDNF     GCACAGAAAGCTCCTGATAGT (Forward)
     CCAGCTTGACTTCTCCTAACC (Reverse)
Rat GDNF    CTACGAAACCAAGGAGGAACTG (Forward)
    CCTTGTCACTTGTTAGCCTTCT (Reverse)
Rat NGF   CTCTGAGGTGCATAGCGTAAT (Forward)
   CTGGGACATTGCTATCTGTGTA (Reverse)
Rat GAPDH CATCTCCCTCACAATTCCATCC (Forward)
 GAGGGTGCAGCGAACTTTAT (Reverse)
Animals. Animal care and procedures were in accordance with the ARVO Statement for the Use of Animals 
in Ophthalmology and Vision Research and approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Utah. The authors confirm that the experimental protocols were approved by 
IACUC and the Institutional Biosafety Committee of the University of Utah. Timed-pregnant Sprague Dawley 
www.nature.com/scientificreports/
1 0SCIENTIfIC REPORTS |  (2018) 8:2003  | DOI:10.1038/s41598-018-20278-4
dams were purchased from Charles River (San Diego, CA). Pups were delivered naturally between embryonic 
days 21 and 23. Animals were maintained under a 12 hour dark/light cycle and had free access to food and water.
Oxygen-induced Retinopathy. The rat 50/10 model of OIR is a well-characterized animal model of 
ROP12,34. Within 6 hours of birth litters were supplemented to contain 12–16 pups, placed into a controlled oxy-
gen chamber (Oxycycler, Biospherix, Parish, New York) with a dam and exposed to oxygen cycling between 50% 
and 10% O2 every 24 hours for 14 days. Animals were placed into room air from p14 to p32. The model creates 
features of OIR pathology (IVNV and AVA) by postnatal day 18 to 20, with regression of abnormal features and 
physiologic vascularization of the avascular retina35. At p32, untreated animals had IVNV of 0.26 ± 0.14 SEM 
% and AVA of 5.62 ± 3.36 SEM%. Animals were euthanized by intraperitoneal injection of ketamine (100 mg/
kg) and xylazine (20 mg/kg) at predetermined time points. Both eyes were collected for flat mount analysis from 
control animals sacrificed at p18 and from one eye of animals sacrificed at p32; the fellow eye was collected for 
immunohistochemistry, or retinas were snap frozen for later RNA or protein analysis. In total, 66 animals from 
6 litters in 3 separate OIR experiments were included in this study. Only retinas with confirmed GFP expression 
were used, as described below in the retinal imaging section.
Subretinal Injections. At the beginning of the 50% O2 cycle on p8, rat pups were given subretinal injections 
of lentiviral vector stock. General anesthesia was induced by inhalation of isoflurane, eye lids were carefully 
teased open and pupils were dilated using tropicamide eye drops 1% (Bausch + Lomb, Bridgewater, New Jersey). 
A 30 G cannula was used to pierce a pilot hole into the sclera near the limbus, a Hamilton syringe with a blunt 
33 G cannula was advanced through the vitreous into the subretinal space and 1 µl lentivirus suspension (con-
taining 106 viral particles) in sterile PBS was slowly injected. Animals were randomly assigned to receive bilateral 
subretinal injections of vehicle (PBS), luciferase shRNA lentivirus (L-lucifshRNA), VEGF164 shRNA lentivirus 
(L-VEGF164shRNA) or VEGF-A shRNA lentivirus (L-VEGFAshRNA); both eyes received the same treatment. 
Pups were returned to their dams and replaced into the Oxycycler within 1.5 hours.
Retinal Imaging. On p18 and p26, all animals were anesthetized using intraperitoneal ketamine and dex-
medetomidine (75/0.5 mg/kg). Tropicamide eye drops 1% were applied to dilate pupils, and corneas were kept 
hydrated with 0.3% hypromellose gel (GenTeal Eye Gel, Novartis). Retinal images were recorded using a contact 
camera for small rodents (Micron IV, Phoenix Research Labs, Pleasanton, CA) under white light illumination 
to visualize the fundus. GFP-positive cells were imaged using a 469/35 nm exciter filter and a 488 nm long pass 
barrier filter. Animals were recovered by intraperitoneal injection of atipamezole (2.5 mg/kg).
Electroretinograms. Rats were fully dark-adapted overnight and subsequently handled under dim red light 
illumination. Anesthesia was induced by intraperitoneal injection of ketamine and xylazine (75/10 mg/kg body 
weight). Pupils were dilated with tropicamide eye drops 1% and corneas lubricated with coupling gel (GenTeal 
Eye Gel, Novartis). Animals were positioned on a heated pad to maintain constant body temperature. Subdermal 
electrodes were used as the ground electrode inserted at the base of the tail and as the reference electrode placed 
between the eyes.
The focal ERG was recorded using the Image-Guided Focal ERG and Micron IV (Phoenix Research Labs). In 
order to allow focal ERGs to be measured in both eyes in some animals, recordings were either made on p28 or 
p29. Since animals were dark-adapted, previous retinal images of GFP were recorded to assure stimuli were only 
obtained in the area of GFP fluorescence. All focal ERG measurements were performed 48 hours after Micron 
imaging so as not to be influenced by prior bleaching of the photoreceptors during imaging. The objective con-
taining the recording electrode was carefully advanced near the cornea and the retinal image was focused under 
red light illumination (850 nm). The recording area (aiming spot size A, 0.5 mm spot diameter) was chosen in 
a central part of the retina approximately one disc diameter away from the optic nerve head, which contained 
GFP-positive cells (Supplemental Fig. 2a). The focal ERG was recorded using LabScribeERG 3 software (Phoenix 
Research Labs) in response to white light flashes (5 ms duration, luminances ranging from −0.40 to 3.20 candela 
per square meter [cd s m−2], with 20 sweeps and 10 second intervals for −0.40 to 1.40 cd s m−2, 10 sweeps and 
20 second intervals for 2.00 cd s m−2, 3 sweeps and 60 second intervals for 2.60 cd s m−2 and 2 sweeps and 2 sec-
ond intervals for 3.20 cd s m−2). Focal ERGs were recorded in 7 eyes treated with L-lucifshRNA, 13 eyes with 
L-VEGF164shRNA and 10 eyes with L-VEGFAshRNA. Scattered light did not contribute to the focal ERG, as 
confirmed by a recording from the optic nerve head at the highest light intensity (Supplemental Fig. 2b).
An LKC UTAS Visual Diagnostic System with BigShot Ganzfeld was used to record the Ganzfeld ERG. 
Measurements were made either on p31 or p32 to allow recordings to be made in both eyes in some animals. A 
corneal contact lens electrode was positioned and the ERG was recorded using white light flashes (5 ms duration, 
luminances ranging from −6.1 to 2.20 cd s m−2, with 30 sweeps and 2 second intervals for −6.1 to −3.6 cd s 
m−2, 3 sweeps and 10 second intervals for −2.4 cd s m−2, 3 sweeps and 20 second intervals for −2.0 cd s m−2, 3 
sweeps and 30 second intervals for −1.6 cd s m−2, 3 sweeps and 40 second intervals for −1.2 cd s m−2, 3 sweeps 
and 60 second intervals for −0.2 cd s m−2, 2 sweeps and 120 second intervals for 1.2 to 2.2 cd s m−2). Ganzfeld 
ERGs were recorded in 10 eyes treated with L-lucifshRNA, 12 eyes with L-VEGF164shRNA and 11 eyes with 
L-VEGFAshRNA.
Comparison to previously published data demonstrates that the a- and b-wave amplitudes of the focal and 
full-field ERGs were reduced in L-lucifshRNA treated retinas compared to untreated eyes and following subret-
inal injection of PBS. This finding provides evidence that ERG recordings were made in transduced areas of the 
retina26.
Optical Coherence Tomography (OCT). Anesthesia was administered by ketamine/dexmedetomidine 
(75/0.5 mg/kg) on p30, pupils were dilated with tropicamide eye drops 1% and coupling gel (GenTeal Eye Gel, 
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Novartis) was applied to maintain corneal hydration. OCT was recorded in all GFP positive eyes using the OCT 
attachment for the Micron IV camera (Phoenix Research Labs). A region containing GFP-positive cells approx-
imately one disc diameter away from the optic nerve head was chosen and a B-scan over 1620 μm with 1024 
A-scans (at a distance of 1.5 μm) was recorded using OCT software (Phoenix Research Labs). GFP fluorescence 
was recorded simultaneously with OCT images. Anesthesia was reversed by intraperitoneal injection of atipame-
zol (2.5 mg/kg). Total retinal thickness and thickness of individual retinal layers was measured using InSight 
software (Phoenix Research Labs). Only high quality OCT images and areas of GFP fluorescence were included 
for OCT analysis, which resulted in measurements over 293–1620 μm (average 787 μm), which corresponds to 
205–1024 A-scans. The thicknesses of the photoreceptor and outer nuclear layers (PRS + ONL), inner nuclear 
layers (INL) and the inner plexiform and ganglion cell layers (IPL + GCL) were determined and measurements 
along the B-scan were averaged for each animal. Thickness measurements were performed on 4 eyes treated 
with L-lucifshRNA, 6 eyes with L-VEGF164shRNA and 4 eyes with L-VEGF-AshRNA was included in the OCT 
analysis.
Immunohistochemistry (IHC) and flat mounts. For immunohistochemistry, eyes were enucleated, 
fixed for 1 hour in 4% PFA in PBS, cryoprotected for 1 hour in 10% sucrose and overnight in 20% sucrose, embed-
ded in a 2:1 mixture of 30% sucrose:optimal cutting temperature compound (Tissue-Tek) on dry ice. 12 μm cross 
sections were cut using a Leica CM3050S cryostat. Cryosections were then washed in PBS and incubated in a 
0.1% Triton X-100 solution, to allow penetrance of DAPI stain, before mounting with DAPI Fluoromount-G 
(SouthernBiotech, Birmingham, AL) and imaged on an Olympus IX81 confocal microscope. From each treat-
ment, a minimum of four sections were sampled from three retinas from three different rats. To insure compa-
rable sampling between treatments, images were captured between 1 and 2 optical fields from the optic nerve 
head. Thickness of the photoreceptor segments and outer nuclear layer (PRS + ONL), inner nuclear layer (INL) 
and inner plexiform and ganglion cell layer (IPL + GCL) were determined using ImageJ. From each image four 
measurements were averaged, resulting in a total of at least 16 values for each layer from each of the three eyes 
per treatment condition.
For flat mounts, eyes were enucleated, fixed for 30 min in 4% PFA in PBS and overnight in HistoChoice tissue 
fixative (Sigma Aldrich), and washed 3 times in PBS. The retina was dissected free, blocked with 10% goat serum 
in 0.5% Triton X-100 in PBS, incubated with isolectin GS-IB4 conjugated with Alexa Fluor 488 for 48 hours and 
mounted with Fluoromount G mounting media (Southern Biotech, Birmingham, AL). Flat mounts were imaged 
using an Olympus IX81 microscope at a X4 magnification and stitched together using MetaMorph software 
((Molecular Devices, Sunnyvale, CA). Areas of avascular area and intravitreal neovascularization were delineated 
using ImageJ software (NIH, Bethesda, MD), as displayed in Supplemental Fig. 3. All flat mounts were analyzed 
by two independent masked reviewers. In the occasional case of a discrepancy in defining a vascular feature, 
images were reviewed together to reach a consensus. Data are expressed as a percentage of avascular/total retinal 
area (AVA) or intravitreal neovascular/total retinal area (IVNV).
Statistical Analysis. Using the rat OIR model to detect statistical significance with a power of 80% and a 
two-sided alpha of 0.05, a sample size of 9 flat mounts/group for AVA and 7/group for IVNV was needed. We 
therefore included at least 9 flat mounts for AVA and IVNV for the p32 time point. Pups from 3 different lit-
ters were used to address biologic diversity. A mixed effects linear regression for statistical comparisons of the 
experimental groups was used to account for clustering effects. OCT analysis of retinal thickness included four 
eyes treated with L-lucifshRNA, six with L-VEGF164shRNA and four with L-VEGFAshRNA. Retinal thickness 
by IHC was determined in at least four sections/eye from three eyes, taken from animals from three different 
litters for each experimental condition. Ganzfeld ERGs were recorded in 10 eyes for L-lucifshRNA, 12 eyes for 
L-VEGF164shRNA and 11 eyes for L-VEGFAshRNA. Focal ERGs were recorded in 7 eyes for L-lucifshRNA, 13 
eyes for VEGF164 shRNA and 10 eyes for VEGF-A shRNA.
To avoid clustering effects by litter, pups nursed by the same dams were randomized to the treatment groups. 
Clustering remained for IHC, for which multiple images were used for analysis from each animal, and for 
Ganzfeld and focal ERG, where both eyes were used in some pups and was accounted for using the mixed effects 
linear regression model. In Ganzfeld and focal ERGs, for which recordings were made at several light intensities, 
we used a linear regression model with a multiple comparison adjustment for the three highest light intensities. 
For graphs, SEMs were determined using post-test marginal estimation from the mixed effects model to account 
for data clustering. For statistical modeling Stata-14 statistical software (College Station, TX, StataCorp LP) was 
used. Results were presented as mean ± SEM.
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